Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Berg and Mount Sinai Hospital Announce Partnership

Published: Saturday, October 12, 2013
Last Updated: Friday, October 25, 2013
Bookmark and Share
Big data approach to focus on biological network models for cancer, central nervous system and endocrine disorders.

Berg and the Icahn School of Medicine at Mount Sinai announced today a pharmaceutical and diagnostic R&D partnership that will leverage the power of multi-omic biology and data analytics to obtain novel insights and potential therapeutics for cancer, central nervous system and endocrine disorders. Over the course of this five-year partnership, Berg will leverage its award-winning Interrogative Biology™ platform in combination with Mount Sinai’s expertise in big data, advanced analytics and biological network modeling.

Berg and Mount Sinai will adopt an innovative risk and return sharing approach, with downstream royalties significantly higher than the industry standard for academia-pharma partnerships. "The partnership with Mount Sinai flips the traditional public-private partnership model and sets a new standard for pharmaceutical research and development," said Niven R. Narain, Co-Founder, President and CTO of Berg.  "Innovation in the healthcare industry extends far beyond scientific and technological advances. In order to address some of the world’s worst health crises, we need to be open to such new and innovative ways of working together.  The fusion of our technologies and expertise are the perfect match to change medicine."

"We are living in an amazing time where new technologies are generating a tremendous amount of health data on an unprecedented scale, revealing novel insights into the mechanism of disease," said Eric Schadt, PhD, The Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai, and Director of the Icahn Institute for Genomics and Multiscale Biology, part of the Mount Sinai Health System. "Working with Berg, we plan to analyze big data and create predictive models to discern similarities and differences in disease patterns, identify the most effective treatment and diagnostics, and ultimately, provide better care for our patients."

Over the course of this partnership, Berg and Mount Sinai will engage in research projects involving the fields of genomics, proteomics, lipidomics, metabolomics and functional phenotypes with the goal to advance treatment options for cancer, CNS and endocrine disorders, as well as inflammation and obesity, and infectious and rare disease patients. Additionally, the partnership hopes to develop diagnostic tools to improve pharmacovigilance, diagnosis of disease and markers of therapeutic efficacy. The agreement was negotiated by Mount Sinai Innovation Partners, which encourages commercialization and partnership opportunities for novel research conducted at Mount Sinai.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!